within Pharmacolibrary.Drugs.ATC.L;

model L04AB02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 6.333333333333333e-06,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0022,
    k12             = 0.538,
    k21             = 0.538
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AB02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Infliximab is a chimeric monoclonal antibody that targets tumor necrosis factor alpha (TNF-α). It is used in the treatment of several autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Infliximab is approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult patients with rheumatoid arthritis, Crohn's disease, and other autoimmune diseases. Typical parameters are for adults (males and females) with standard IV dosing regimens.</p><h4>References</h4><ol><li><p>Schreiber, S, et al., &amp; Reinisch, W (2021). Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. <i>Gastroenterology</i> 160(7) 2340–2353. DOI:<a href=&quot;https://doi.org/10.1053/j.gastro.2021.02.068&quot;>10.1053/j.gastro.2021.02.068</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33676969/&quot;>https://pubmed.ncbi.nlm.nih.gov/33676969</a></p></li><li><p>Hemperly, A, &amp; Vande Casteele, N (2018). Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. <i>Clinical pharmacokinetics</i> 57(8) 929–942. DOI:<a href=&quot;https://doi.org/10.1007/s40262-017-0627-0&quot;>10.1007/s40262-017-0627-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29330783/&quot;>https://pubmed.ncbi.nlm.nih.gov/29330783</a></p></li><li><p>Smith, PJ, et al., &amp; Subramanian, S (2022). Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. <i>Journal of Crohn&#x27;s &amp; colitis</i> 16(9) 1436–1446. DOI:<a href=&quot;https://doi.org/10.1093/ecco-jcc/jjac053&quot;>10.1093/ecco-jcc/jjac053</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35390141/&quot;>https://pubmed.ncbi.nlm.nih.gov/35390141</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AB02;
